Prospection has announced a unique global data access agreement with Medical Data Vision Co., Ltd. (MDV) to accelerate healthcare analytics globally. The agreement, covering the world's second pharmaceutical market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in Japan at more than 470 hospitals. Combining  predictive analytics and machine learning with real-world healthcare data, Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across Japan, unlocking potential to assess an unlimited number of treatment programs in the region.

The agreement  also enables access to patient history and prefecture level data, allowing analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where development can address unmet needs.  When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Prospection's access to Japan's most comprehensive medical data sets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions globally including Australia, New Zealand, Japan, South Korea, Taiwan, USA and the UK.

The company's latest announcement with Medical Data Vision will build on this work, providing Prospection with access to one of Japan's healthcare databases. By enabling pharmaceutical companies and health researchers across the globe to better understand the full cycle of  health conditions and disease journeys, this data will allow global life science companies to: 1.  Collect patient and market insights Through the analysis of specific health conditions and patient journeys, pharmaceutical companies can determine where, when and how to invest their resources and how to position their brand within the Japanese pharmaceutical market while forecasting supply chain, and developing models for market access. 2. Find patients and develop tactical plans Life science companies can utilise the data to identify where patients with the disease burden for their treatment offerings are being treated geographically.  Companies can then deploy their regional in-field teams with the right messages to support clinicians to help these patients requiring treatment.

3.  Publish data Access to one of the most comprehensive Japanese medical data sets also creates an opportunity to add to the clinical body of evidence for health conditions to help inform a better understanding of specific diseases.  4.  Receive decision support Provide healthcare providers with trigger events to assist with targeted education when it is needed most, supporting clinician at point of care with the patient.